|
 Symbiosis Pharmaceutical Services (Symbiosis), a world-class contract development and manufacturing organisation located in Stirling and a specialist GMP aseptic fill-finish manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally, has appointed Jos Vergeest as senior business development director.
Jos Vergeesthas three decades of commercial pharmaceutical experience to support the company's international growth ambitions. Having spent fifteen years in sales, marketing and management roles at GSK and AstraZeneca he then moved into contract development and manufacturing with HALIX, supporting its growth from start-up to mid-sized contract development and manufacturing organisation. His most recent position was with Wacker Biotech, where he was responsible for business development activities in Europe and Asia.
Jos Vergeest commented: “Pharmaceutical companies are looking for contract development and manufacturing organisations that offer real partnerships, which means understanding their needs, thinking alongside them and providing genuine flexibility, responsiveness and open communication. For me, business development is about building the trust that allows us to solve challenges together.”
His first-hand experience of supporting a specialist contract development and manufacturing organisation’s scale-up aligns closely with Symbiosis building on a £26 million investment programme, which has expanded its sterile manufacturing capacity for larger-scale clinical and commercial programmes.
Based in the Netherlands, Jos will work closely with the wider Symbiosis team to establish new strategic partnerships, cement existing client relationships and ensure market and customer insight continues to inform Symbiosis’ growth plans across the Benelux and DACH regions.
Joanne Anderson, Symbiosis Pharmaceutical Services’ chief commercial officer, said: “Jos understands the challenges that pharmaceutical companies face, and has spent a large part of his career helping drug developers work effectively with specialist manufacturing partners. He also brings first-hand experience of a Contract Development and Manufacturing Organisation expanding its capacity and client base while protecting the quality and personal service customers value. That experience will be extremely valuable as Symbiosis continues to grow.”
Headquartered in Stirling, Scotland, Symbiosis Pharmaceutical Services is a specialist aseptic fill-finish Contract Development and Manufacturing Organisation, manufacturing injectable medicines for pharmaceutical and biotechnology companies for clinical trials and commercial supply.
Symbiosis Pharmaceutical Services is MHRA-licensed and US FDA-inspected and offers a range of services including product development, the aseptic fill-finish of injectable drug products into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines.
The Symbiosis Pharmaceutical Services facilities in Stirling, UK, were designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring aseptic injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.
Regulatory compliance, technical capability, and operational flexibility are core to the Symbiosis value proposition, along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.
|